Status:
UNKNOWN
WHENII - Early Response Evaluation With FDG-PET/CT and Liquid Biopsy in Patients With NSCLC
Lead Sponsor:
Rigshospitalet, Denmark
Conditions:
Non Small Cell Lung Cancer
Circulating Tumor Cell
Eligibility:
All Genders
Phase:
NA
Brief Summary
Response evaluation with FDG-PET and free circulating DNA in patients with inoperable lung cancer of non small cell type during first treatment with chemotherapy or immunotherapy.
Detailed Description
Interventional study of patients with inoperable lung cancer of non small cell type undergoing 1st treatment of either chemotherapy or immunotherapy. Patients are evaluated with FDG-PET/ct and blood a...
Eligibility Criteria
Inclusion
- Patients with non-small cell lung cancer (NSCLC) who is about to start treatment with chemo- or immune therapy. No prior treatment of the one given.
- Measurable decease according to RECIST criteria
- Age \> 18 years
- Performance status 0-2 (0-1 for immunotherapy)
- Understands and reads danish
Exclusion
- Poor performance status
- Secondary active cancer
- Pregnancy
- Dysregulated diabetes mellitus
Key Trial Info
Start Date :
February 28 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03481101
Start Date
February 28 2018
End Date
February 28 2021
Last Update
October 8 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University Copenhagen
Copenhagen, Denmark, 2200
2
University of Copenhagen
Copenhagen, Denmark